Publications by authors named "B L Dowell"
Background: Frequently, subjects offered colonoscopy due to symptoms of colorectal neoplasia are diagnosed with diverticula. The symptoms may, however, also be related to extra-colonic neoplasia. The present retrospective study evaluated a possible association between increased levels of predefined biomarkers in subjects diagnosed with diverticula and risk of developing a primary malignant disease.
View Article and Find Full Text PDFArticle Synopsis
- The study examined the relationship between higher levels of cancer-related biomarkers in patients with no detected issues during a large bowel endoscopy and their risk of developing malignant diseases over time.
- Increased levels of biomarkers TIMP-1, CEA, CA19-9, and YKL-40 were linked to a higher likelihood of subsequent malignancy, with statistical significance noted in the analysis.
- Specifically, the risk of developing malignant diseases within 5 years was greater for those with one or more elevated biomarkers, suggesting that even in the absence of visible pathology, raised biomarker levels can be an important indicator of future health risks.
Objectives: Linifanib, a potent and selective inhibitor of the tyrosine kinase activity of vascular endothelial growth factor and platelet-derived growth factor receptors, has clinical activity in advanced non-small cell lung cancer (NSCLC) both as monotherapy in the relapsed setting or with carboplatin and paclitaxel in the first-line setting. Though benefit was observed in unselected patient populations, identification of predictive biomarkers is critical for further development of this novel agent.
Materials And Methods: Data from 4 randomized studies in relapsed NSCLC with linifanib (n=116) or other treatments (n=125) were examined in an exploratory analysis to identify a biomarker profile predictive of favorable survival.
Background/aim: The combination of plasma tissue inhibitor of metalloproteinases-1 (1) and CEA has been shown to have utility in early detection of colorectal cancer (2). A prospective study was performed to validate previous findings.
Patients And Methods: Individuals undergoing large bowel endoscopy were prospectively included (N=1965).
Background: The efficacy and safety of linifanib (ABT-869), a selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinases, were assessed in this phase 2, single-arm, open-label, multicenter trial.
Methods: Eligible patients had unresectable or metastatic hepatocellular carcinoma and had received ≤ 1 prior systemic therapy. Patients received oral linifanib at a fasting dose of 0.